Expression of LAT1 and 4F2hc in Gastroenteropancreatic Neuroendocrine Neoplasms.

Yosuke Horita, Kyoichi Kaira, Tomonori Kawasaki, Yoshiaki Mihara, Shinichi Sakuramoto, Shigeki Yamaguchi, Kojun Okamoto, Shomei Ryozawa, Yoshikatsu Kanai, Masanori Yasuda, Tetsuya Hamaguchi

In vivo (Athens, Greece) 2021 Jul-Aug

filter terms:

Little is known about the expression of L-type amino acid transporter 1 (LAT1) and 4F2hc in gastroenteropancreatic-neuroendocrine neoplasms (GEP-NENs). Hence, we conducted a study to verify the clinicopathological significance of LAT1 and 4F2hc. Tissues from 126 patients with GEP-NENs were collected between August 2007 and August 2019 at our institution. We evaluated LAT1 and 4F2hc expression by immunohistochemistry, and examined their clinical significance. No statistically significant associations were observed between LAT1 expression and the different NENs. Expression of 4F2hc was significantly different between neuroendocrine tumour (NET)-G1, NET-G2, and NET-G3 (p=0.029), and was significantly associated with vascular invasion (p=0.044) and the Ki-67 index (p=0.042). No association between LAT1 expression and malignant features in GEP-NENs was observed. However, an association between 4F2hc expression and the potential of malignancy in GEP-NENs was evident. Copyright © 2021 International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.

Citation

Yosuke Horita, Kyoichi Kaira, Tomonori Kawasaki, Yoshiaki Mihara, Shinichi Sakuramoto, Shigeki Yamaguchi, Kojun Okamoto, Shomei Ryozawa, Yoshikatsu Kanai, Masanori Yasuda, Tetsuya Hamaguchi. Expression of LAT1 and 4F2hc in Gastroenteropancreatic Neuroendocrine Neoplasms. In vivo (Athens, Greece). 2021 Jul-Aug;35(4):2425-2432